152 related articles for article (PubMed ID: 3146198)
1. Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells.
Shimazaki C; Atzpodien J; Wisniewski D; Gulati SC; Kolitz JE; Fried J; Clarkson BD
Acta Haematol; 1988; 80(4):203-9. PubMed ID: 3146198
[TBL] [Abstract][Full Text] [Related]
2. Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing.
Atzpodien J; Gulati SC; Shimazaki C; Bührer C; Oz S; Kwon JH; Kolitz JE; Clarkson BD
Oncology; 1988; 45(6):437-43. PubMed ID: 3263598
[TBL] [Abstract][Full Text] [Related]
3. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patients.
Shiiba K; Suzuki R; Kawakami K; Ohuchi A; Kumagai K
Cancer Immunol Immunother; 1986; 21(2):119-28. PubMed ID: 3081248
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
6. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
7. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
8. Generation and characterization of lymphokine-activated killer cells against fresh human leukemia cells.
Tahara T; Iseki R; Morishima Y; Yokomaku S; Ohno R; Saito H
Jpn J Cancer Res; 1988 Mar; 79(3):390-9. PubMed ID: 3131287
[TBL] [Abstract][Full Text] [Related]
9. [Low susceptibility of choriocarcinoma cell lines to lymphokine activated killer (LAK) cells].
Kameda T; Negoro T; Hagiwara M; Koyama M; Matsuzaki N; Saji F; Tanizawa O
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):1-6. PubMed ID: 2784473
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells.
Oshimi K; Oshimi Y; Akutsu M; Takei Y; Saito H; Okada M; Mizoguchi H
Blood; 1986 Oct; 68(4):938-48. PubMed ID: 3489494
[TBL] [Abstract][Full Text] [Related]
11. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
12. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
Blanchard DK; Djeu JY
J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
[TBL] [Abstract][Full Text] [Related]
13. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
14. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
Chong AS; Scuderi P; Grimes WJ; Hersh EM
J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
[TBL] [Abstract][Full Text] [Related]
15. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of interleukin-2-activated lymphocytes for autologous normal blood mononuclear cells.
Oshimi K; Oshimi Y; Saito H; Mizoguchi H
J Immunol Methods; 1988 May; 109(2):161-8. PubMed ID: 3258896
[TBL] [Abstract][Full Text] [Related]
18. Resistance of some leukemic blasts to lysis by lymphokine activated killer (LAK) cells.
Panayotides P; Porwit A; Sjögren AM; Wasserman J; Reizenstein P
Eur J Haematol; 1988 Apr; 40(4):362-7. PubMed ID: 3259192
[TBL] [Abstract][Full Text] [Related]
19. Tumour necrosis factor-alpha enhances the cytolytic and cytostatic capacity of interleukin-2 activated killer cells.
Matossian-Rogers A; Browne C; Turkish M; O'Byrne P; Festenstein H
Br J Cancer; 1989 Apr; 59(4):573-7. PubMed ID: 2785398
[TBL] [Abstract][Full Text] [Related]
20. Recombinant interleukin 4 (RIL4) inhibits interleukin 2-induced activation of peripheral blood lymphocytes.
Han X; Itoh K; Balch CM; Pellis NR
Lymphokine Res; 1988; 7(3):227-35. PubMed ID: 3263554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]